Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will report its 2025 third quarter financial results on Wednesday, November 5, 2025 after the U.S. market close. Management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss the results and provide a business and financial update.

Participants may register in advance via the Investors section of the Jazz Pharmaceuticals website and are recommended to register at least 15 minutes before the webcast. A replay will be available in the Investors events and presentations area.

Jazz Pharmaceuticals is a global biopharma company focused on therapies for sleep disorders, epilepsy, and oncology, headquartered in Dublin with global R&D and manufacturing operations.

News Market Reaction – JAZZ

-0.25%

1 alert

-0.25% News Effect

On the day this news was published, JAZZ declined 0.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss 2025 third quarter financial results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-third-quarter-financial-results-on-november-5-2025-302590829.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals (JAZZ) report Q3 2025 results?

Jazz will report Q3 2025 results on Wednesday, November 5, 2025 after the U.S. market close.

What time is the Jazz (JAZZ) Q3 2025 earnings webcast?

The live audio webcast is scheduled for 4:30 p.m. EST / 9:30 p.m. GMT on November 5, 2025.

How can investors register for the Jazz Pharmaceuticals (JAZZ) November 5, 2025 webcast?

Investors can register in advance via the Investors section of the Jazz Pharmaceuticals website; registration is recommended at least 15 minutes before the webcast.

Will a replay of the Jazz Pharmaceuticals (JAZZ) Q3 2025 webcast be available?

Yes. A replay will be available via the Investors section under Events & Presentations on the Jazz Pharmaceuticals investor website.

What topics will Jazz Pharmaceuticals (JAZZ) cover in the November 5, 2025 update?

Management will discuss the 2025 third quarter financial results and provide a business and financial update.